AstraZeneca Q3 Earnings Exceed Estimates Driven by Oncology Growth
AstraZeneca (AZN) reported third-quarter core earnings per share of $2.79, representing a 19% increase at constant exchange rates. This performance surpassed analyst expectations of $2.62, fueled primarily by strong sales within the company's oncology division. Following the announcement, AstraZeneca shares rose 3.5% in premarket trading. The robust growth in cancer treatments highlights the company's successful expansion in high-demand therapeutic sectors, reinforcing its market position despite global economic fluctuations.
Tickers: $AZN